Genomic sequencing studies in the past several years have yielded a large number of cancer somatic mutations. There remains a major challenge in delineating a small fraction of somatic mutations that are oncogenic drivers from a background of predominantly passenger mutations. Although computational tools have been developed to predict the functional impact of mutations, their utility is limited. In this study, we applied an alternative approach to identify potentially novel cancer drivers as those somatic mutations that overlap with known pathogenic mutations in Mendelian diseases. We hypothesize that those shared mutations are more likely to be cancer drivers because they have the established molecular mechanisms to impact protein functions. We first show that the overlap between somatic mutations in COSMIC and pathogenic genetic variants in HGMD is associated with high mutation frequency in cancers and is enriched for known cancer genes. We then attempted to identify putative tumor suppressors based on the number of distinct HGMD/COSMIC overlapping mutations in a given gene, and our results suggest that ion channels, collagens and Marfan syndrome associated genes may represent new classes of tumor suppressors. To elucidate potentially novel oncogenes, we identified those HGMD/COSMIC overlapping mutations that are not only highly recurrent but also mutually exclusive from previously characterized oncogenic mutations in each specific cancer type. Taken together, our study represents a novel approach to discover new cancer genes from the vast amount of cancer genome sequencing data.
Introduction
Significant efforts in the past several years in cancer genomic sequencing by individual investigators and large consortium such as The Cancer Genome Atlas (TCGA) and The International Cancer Genome Consortium (ICGC) have uncovered a large number of novel oncogenic drivers. These studies not only advanced our understanding on the genetic basis of tumorigenesis and cancer progression, but also significantly enabled the development of personalized cancer therapeutics 1, 2 . Cancer genome or exome sequencing data have been generated from approximately 25,000 tumor samples covering more than 50 tumor types 3, 4 , representing a comprehensive cancer genomic atlas. While data generation has been greatly facilitated by rapid technology development, interpretation of cancer sequence information still remains a major challenge. As most solid tumors harbor a median of 40-80 non-synonymous somatic mutations per tumor, only three to six of them are driver mutations 5 . The most commonly used approach to distinguish a small number of driver mutations from those background passenger mutations is to identify significantly mutated genes in a cohort study 6 . The underlying rationale is if a gene is mutated at significantly greater rate than the background mutation rate, it is more likely to be oncogenic, as the mutations conferring tumor growth advantage are evolutionarily selected during cancer development. To complement this approach, various computational tools have been developed to assess the effects of missense mutations on protein functions 7 . While such an approach has further characterized numerous novel cancer drivers and oncogenic pathways from cancer genomic sequencing data, it requires a large number of samples to uncover those drivers mutated at low population frequency in a given tumor type. This is particularly problematic for those cancers with high background mutation rates such as melanomas and lung cancers. For example, it has been estimated that it would require approximately 4,000 melanoma patient samples to detect cancer genes mutated at 2% frequency, and more than 20,000 samples for genes mutated at 1% with 90% power for 90% of genes 8 . Many human genetic diseases are Mendelian disorders caused by one or more aberrations in the genome. These diseases are often heritable as the disease causing, pathogenic variants are passed on from parents' genome. To date, approximately 180,000 genetic variants in more than 7,000 genes have been identified as pathogenic for more than 4,000 Mendelian diseases 9 . Some of the first established cancer genes with frequent somatic mutations were originally identified from their associations with familial cancer syndromes. The first tumor suppressor RB1 was discovered by studying the familial form of retinoblastoma 10 . The most frequently mutated gene in cancers, p53, was also identified as a tumor suppressor inactivated in Li-Fraumeni syndrome, a rare cancer predisposition hereditary disorder. Other well-known cancer genes harboring high frequency somatic mutations and that are associated with Mendelian diseases include VHL in Von Hippel-Lindau syndrome, MLH1, MSH2, MSH6 in Lynch syndrome, TSC1, TSC2 in Tuberous sclerosis, and ATM in ataxia-telangiectasia 11 . Notably, a recent study has revealed potentially novel cancer-associated genes through analysis of comorbidity between cancers and Mendelian diseases 12 . By definition, germline pathogenic variants impact the functions of key proteins involved in the developmental process and consequently cause heritable diseases. If the same germline pathogenic variants occur as somatic mutations in cancers, these mutations would also alter protein functions and may play a role in tumor initiation and progression, even though the same proteins can have very different functions during development than in adult tissues. Indeed in a recent report, several genes sharing identical mutations in Mendelian diseases and cancers were proposed as novel cancer genes 13 . Based on this underlying hypothesis, we carried out a systematic comparative analysis of the reported pathogenic variants in Mendelian diseases and cancer somatic mutations. There are several repositories for pathogenic variants. A comparison of four of the most comprehensive databases showed that HGMD is currently the largest collection of human disease variants, although each database has its own advantages in terms of the information collected as well as database infrastructure 9 . For cancer somatic mutations, COSMIC is recognized as the most comprehensive resource for somatic mutations in human cancers 14 , with more than 1.4 million confirmed somatic mutations identified from 1.1 million tumor samples including genome-wide sequencing data from more than 20,000 tumors. In this study, we first identified overlapping mutations between pathogenic variants in HGMD 15 and cancer somatic mutations from the COSMIC database 14 . Further characterization of these mutations show that the mutation-harboring genes are significantly enriched for known cancer genes, supporting the above described hypothesis. We then examined those genes harboring the shared pathogenic variants and somatic mutations in cancers by applying additional filters such as the number of overlapping HGMD/COSMIC mutations in a given gene or the frequency of overlapping mutations in each tumor type. Moreover, those overlapping mutations with high recurrence in cancers were subjected to mutual exclusivity analysis with known oncogenes in each tumor type in order to identify novel oncogenic drivers. Taken together, our study represents a novel approach to discover new cancer genes from the vast amount of cancer genome sequencing data. Table: refGene). Cancer Gene Census dataset was downloaded from http://cancer.sanger.ac.uk/census/.
Methods

COSMIC
All the analyses were performed using shell scripts, mysql scripts and R scripts. The mutual exclusivity heat map was generated using gitools (http://www.gitools.org/). The survival analysis was done through cBioPortal (http://www.cbioportal.org/). Several major scripts for database query and statistical analyses are available on github (https://github.com/CosmicHGMD/CancerMendelian).
Results
Identification of overlapping pathogenic variants in HGMD and somatic mutations in COSMIC
HGMD includes six classes of variants, and we only included disease-causing mutations (DM and DM?) in our analysis. The DM class variants have been demonstrated in literature to confer the associated clinical phenotype of the affected individuals. The DM? class variants have some degree of uncertainty, but nevertheless have strong evidence supporting their pathogenicity. At the time of this writing, there are a total of 153,593 DM/DM? class variants in HGMD database. 11,523 of these variants are present in the COSMIC database, representing 0.54% of the total mutations in COSMIC (Table 1) . When we only include the confirmed somatic mutations in COSMIC, there are 8,582 mutations (0.6%) that overlap with HGMD DM/DM? variants. As the majority of the somatic mutation data in COSMIC are from cancer genomic sequencing studies, some of these mutations are likely false positives, particularly those from early whole genome/exome sequencing when computational methods for calling somatic mutation were less reliable or if the identified somatic mutations were not validated by a different sequencing platform. Therefore, we further restrict COSMIC data to include only those somatic mutations occurred in more than one tumor samples. Although the total number of overlapping mutations with HGMD DM/DM? variants is reduced to 3,470, using this limited but more reliable somatic mutation list, the percentage with respect to the total number of these recurrent mutations (215, 436) in COSMIC increases to 1.6% (Table 1) , suggesting Mendelian disease pathogenic variants are over-represented in recurrent somatic mutations in cancers.
Then we randomly selected the same number of genetic variants (153,593) from 1000 genome (exonic region) or the ExAC database as control variant datasets, and performed the same analysis. The analysis of randomly selected, mostly non-pathogenic common genetic variants was repeated 1000 times, and the results indicated that percentages of common non-pathogenic variants overlapping with COSMIC mutations are lower than the HGMD pathogenic variants ( Table 1) . The statistical significance was assessed based on the distribution of results from 1000 simulations. This finding supports our initial hypothesis that overlapping pathogenic variants in HGMD with cancer somatic mutations could enable identification of novel cancer genes. Next, we tested if HGMD/COSMIC overlapping mutations are more likely to occur at high frequency in cancers than those somatic mutations non-overlapping with HGMD. We first divided the confirmed COSMIC somatic mutations into two groups. The first group includes those mutations overlapped with HGMD DM/DM? variants and the second group includes the rest of somatic mutations that are only present in the COSMIC database. Then, for a given recurrence frequency cutoff c, we computed the percentage of somatic mutations with recurrence frequency (f) greater than c in group 1 (denoted as % 1 > ) and those in group 2 (denoted as % 2 > ). This is followed by computing the ratio of % 1 > over % 2 > at various mutation frequencies. As illustrated in Figure 1A , as the recurrence frequency (x-axis) increases, this ratio (y-axis) also increases. For example, the ratio is approximately 25 for recurrence frequency 20, indicating that COSMIC mutations overlapping with HGMD pathogenic variants are 25 fold more likely to occur in more than 20 tumor samples than those not overlapping with HGMD variants. We also directly plotted % 1 > and % 2 > (Figure 1B ), and it clearly shows the HGMD/COSMIC overlapping mutations have higher mutation frequencies than those mutations only in the COSMIC database with mean recurrence in 8.0 and 1.3 tumors respectively (p = 1.5E-5, one-sided t-test). Because the likelihood that a somatic mutation is a cancer driver increases with its mutation frequency in cancers, this result is consistent with the hypothesis that cancer mutations overlapping with germline disease pathogenic variants in HGMD are more likely to be oncogenic. We further examined the presence of known cancer genes in the two groups using cancer gene census annotation 16 . While only 4.3% of the COSMIC somatic mutations do not overlap with HGMD are in the cancer gene census list, there are approximately 10% of the somatic mutations overlapping with HGMD occur in cancer census genes.
To determine if the combination of somatic mutation frequency and the presence of overlap with HGMD pathogenic mutations would facilitate cancer gene discovery, we computed the percentage of somatic mutations mapped to cancer census genes in all COSMIC confirmed somatic mutations or only in those overlapped with HGMD DM/DM? variants. This procedure was then repeated for mutations with increasing frequencies (Figure 2 ). Two observations were notable from the results. First, a somatic mutation is more likely to be in a cancer gene as its frequency increases, evidenced by increasing percentage of cancer census genes. Second, the probability that the mutation-harboring genes are cancer-related increases if there are overlapping with HGMD variants (Figure 2 , red bars vs. blue bars). 
Identification of potential tumor suppressors
We examined whether the number of distinct overlapping HGMD/COSMIC mutations in a given gene is associated with the probability that the gene is a cancer gene. Figure 3 shows that as the number of distinct overlapping HGMD/COSMIC mutations in a given gene increases, the percentage of genes that belong to cancer gene census increases as well. Of those genes with more than six distinct overlapping mutations, approximately 25% are present in cancer gene census. It is generally recognized that while oncogenes are often mutated recurrently at certain positions (referred as hotspots), tumor suppressors tend to lack such mutational hotspots and are mutated at many positions across the gene sequences. Therefore, we reason that identifying genes with high number of distinct overlapping HGMD/COSMIC mutations would allow us to discover potentially novel tumor suppressors.
Accordingly, we ranked all the genes in COSMIC based on the number of distinct somatic mutations that overlap with HGMD DM/DM? variants and provided both cancer gene census annotations as well as oncogene/tumor suppressor classifications according to Vogelstein et al. 5 in Table 2 . Almost half (23/48) of the genes with at least 20 overlapping HGMD/COSMIC mutations are in the cancer gene census list and/or annotated as an oncogene or a tumor suppressor, furthering the notion that HGMD pathogenic variant annotation may help distinguish driver oncogenic mutations from the passenger mutations in tumors. As expected, most of those genes with oncogene/tumor suppressor annotations are classified as tumor suppressors (19/21, 90%; Table 2 ). A literature search has provided support that some of the remaining genes are likely novel tumor suppressors. There are several genes that encode ion channels with many HGMD/COSMIC overlapping mutations, including SCN5A (67 overlapping mutations), SCN1A (52), CFTR (48), RYR1 (36) and RYR2 (30) ( Table 2 ). While ion channels have not been recognized as a major class of cancer related genes, emerging evidence suggest at least some ion channels are involved in promoting malignancy. For example, CFTR, the cystic fibrosis (CF) gene, has been postulated to be a tumor suppressor because loss of CFTR enhanced tumor cell proliferation and epithelial-to-mesenchymal transition, and is associated with poor prognosis in several cancer types 17, 18, 19 . We also observed multiple collagen family genes with significant overlap between HGMD and COSMIC mutations, such as COL3A1 (29 overlapping mutations), COL7A1 (22) ( Table 2 ), COL1A2 (19), COL4A5 (18), COL2A1 (14), COL6A3 (13), COL1A1 (13), and COL4A4 (11) (data not shown). Although collagens are considered as a barrier to suppress angiogenesis since they are key components of extracellular matrix in tumor microenvironment, only recent functional studies have shown a causal relationship between loss of collagens and tumor progression 20 . Our results suggest that collagens may represent another new class of tumor suppressors. Notably, two genes FBN1 and TGFBR2, associated with a genetic disorder of connective tissue known as Marfan syndrome 21, 22 , had 43 and 22 HGMD/COSMIC overlapping mutations respectively. Upon further investigation, we found that the two genes are mutated frequently in lung squamous cell carcinomas (SCCs) with a combined mutation frequency 10% in the TCGA cohort 23 . Moreover, FBN1 and TGFBR2 mutations are associated with poor survival. As shown in Figure 4 , FBN1 mutation-harboring lung SCCs had poor disease progression free survival (DFS) (Figure 4A ), and those patients with TGFBR2 mutations had both poor DFS and overall survival (OS) (Figure 4B, 4E) . The combined FBN1 and TFGBR2 mutations are associated with both poor DFS and OS ( Figure 4C, 4F) . TSG  PKHD1  31  NF1  148  Yes  TSG  SMAD4  31  Yes  TSG  PTEN  145  Yes  TSG  PTPN11  31  Yes  Oncogene  RB1  91  Yes  TSG  RYR2  30  SCN5A  67  COL3A1  29  CDKN2A  66  Yes  TSG  MLH1  29  Yes  TSG  NF2  65  Yes  TSG  BRCA1  29  Yes  TSG  KMT2D  56  Yes  MSH2  28  Yes  TSG  F8  56  VWF  27  MYH7  54  TSC2  27  Yes  SCN1A  52  STK11  27  Yes  TSG  USH2A  50  PTCH1  27  Yes  TSG  ATM  50  Yes  TSG  ATP7B  25  MEN1  49  Yes  TSG  WT1  24  Yes  TSG  CFTR  48  TGFBR2  22  FBN1  43  PAH  22  HNF1A  39  Yes  TSG  IRF6  22  RET  39  Yes  Oncogene  COL7A1  22  ABCA4  37  CASR  22  RYR1  36  APOB  22  BRCA2  36  Yes  TSG  GCK  21  LDLR  35  MYBPC3  20 
Identification of potential oncogenes
To identify putative oncogenes from the overlapping HGMD/COSMIC mutations, we applied two criteria. First, as most well-known oncogenic, activating mutations are highly recurrent in a specific tumor type, we ranked HGMD/COSMIC overlapping mutations by their mutation frequency. This was done separately for each tumor type in COSMIC. Second, because different oncogenic mutations in a given tumor type are often mutually exclusive, we performed mutual exclusivity analysis to identify those HGMD/COSMIC overlapping mutations that are not only highly recurrent but also mutually exclusive from mutations in known oncogenes based on oncogene classification by Vogelstein et al 5 . To achieve sufficient statistical power in mutual exclusivity analysis, we only analyzed 19 tumor types with at least 200 samples that had whole genome or exome sequencing data in COSMIC and focused on those HGMD/COSMIC overlapping mutations in non-cancer genes (oncogene or tumor suppressor according to Vogelstein et al.) that are mutated in at least 1% of the total samples in a specific tumor type. Interestingly, of the 19 tumor types we analyzed, only endometrium, large intestine, and upper aero-digestive tract (UADT) cancers had such mutations, indicating that while only a very small percentage of COSMIC somatic mutations overlap with HGMD pathogenic variants (Table 1) , even fewer are mutated in cancers with high recurrence. Notably, the ACVR1 R206H mutation occurred in 3 endometrium cancer samples, and an additional endometrium tumor harbors the ACVR1 G356D mutation. Mutual exclusivity analysis revealed that 3 of these 4 samples are mutually exclusive from the most frequently mutated oncogene PIK3CA, CTNNB1 and KRAS in this tumor type (p-value = 0.078; Figure 5 ). Since the above approach combining high mutation frequency and mutual exclusivity from known oncogenic drivers in each specific tumor type led to very few candidates as putative oncogenic mutations, we ranked somatic mutations only based on frequency across all cancer types in COSMIC without taking mutual exclusivity into consideration (Table 3 ). Many oncogenes have multiple mutational hotspots, and therefore for each gene we only show the mutation (at amino acid level) with the highest recurrence. Of genes with the most recurrent amino acid change occurring in at least 15 tumors, 18 had oncogene/tumor suppressor annotations (Table 3) . While 50% (9/18) are classified as oncogenes, the presence of many tumor suppressors is not surprising because mutational hotspots (typically dominant negative mutations) are also observed in some tumor suppressors such TP53 24 . The remaining genes without oncogene/tumor suppressor annotations provide possible candidate oncogenes due to the presence of mutational hotspots. It is noteworthy that there are 3 protein kinases that had a recurrent somatic mutation detected in more than 10 but less than 15 tumor samples: RAF1, p.S257L, 13 tumors; FGFR4, p.G388R, 12 tumors; TYK2, p.V362F, 12 tumors. Although the 3 kinases are not recognized as oncogenes, there are strong evidences that these recurrent mutations are activating and/or oncogenic 25, 26, 27 , suggesting RAF1, FGFR4 and TYK2 are likely novel oncogenes.
Discussion
Owing to technological advancement and cost reduction, genomic sequencing is a new paradigm in cancer research and personalized cancer therapeutics. A large number of cancer somatic mutations have been described from whole genome/exome sequencing studies. As only a small percentage of somatic mutations are cancer drivers, it is of paramount importance to distinguish those driver mutations from a background of predominantly passenger mutations. Although many computational methods have been developed to predict the functional consequences of mutations 7 , it has been indicated that their utility is limited 28 . In this study, we applied an alternative approach to discover cancer drivers from genomic sequencing data. By overlapping cancer somatic mutations and well-defined pathogenic disease-causing germline variants in Mendelian diseases, we identified putative tumor suppressors and oncogenes, which warrant follow-up functional studies. Our analyses suggested that ion channels, collagens and Marfan syndrome-related genes may represent new classes of tumor suppressors. More significantly, mutations in two Marfan syndrome-related genes FBN1 and TGFBR2 are associated with poor prognosis in lung squamous cell carcinomas, providing novel biomarkers with potential clinical relevance in areas of prevention, diagnosis and treatment 29 . Although the previous report by Zhao and Pritchard 13 also interrogated overlapping pathogenic mutations in inherited diseases and cancer somatic mutations, we applied a novel approach to identify candidate tumor suppressors and oncogenes separately based on different criteria. Our approach is particularly useful in identifying the above highlighted putative tumor suppressors. Table 3 . Genes ranked by mutation frequency of the most recurrent HGMD-COSMIC overlapping mutation (at amino acid level) for each gene. Tumor samples with genome-wide sequencing data were used in the analysis. Only genes with the most recurrent amino acid change in at least 15 tumors are shown. TSG: tumor suppressor gene. From our analyses, we rediscovered genes with cancer predisposing mutations, including TP53, APC, VHL, RB1 and many others (Table 2) , which enhanced our confidence in the approach. However, as these genes have been well studied with respect to both germline mutations in familial cancer syndromes and somatic mutations in cancers, our focus lies on those genes with unknown connections between Mendelian diseases and specific cancers associated with the identical mutations. As genes often function differently in development versus in adult tissues, it is critical to further investigate the molecular pathways modulated by those genes in order to understand the mechanisms by which the same mutations can cause Mendelian diseases during development and drive tumor growth in adult tissues. This is best illustrated by an example in our oncogene discovery that revealed 5 HGMD/COSMIC overlapping mutations in ACVR1 gene cumulatively occurred in 19 central nervous system (CNS) cancers (data not shown). While the 5 ACVR1 mutations in germline cause fibrodysplasia ossificans progressiva (FOP), an autosomal dominant disorder of skeletal malformation and disabling heterotopic ossification 30 , the same mutations are somatic oncogenic drivers in a subtype of CNS cancers, specifically diffuse intrinsic pontine glioma (DIPG) 31 . Functional studies have demonstrated the ACVR1 mutations in germline activate the canonical bone morphogenic protein (BMP) pathway to promote osteogenic differentiation and endochondral bone formation resulting in FOP, and the same BMP pathway activated by these mutations in astrocyte cells in the brain accelerates cell proliferation ultimately leading to malignancy 32 . Therefore, these seemingly unrelated two diseases involving different tissue and cell types might be connected by the same molecular pathway activated by identical mutations in germline or in somatic cells. As described in the results section, two of these five mutations are also present in endometrium cancers, and they are largely mutual exclusive from the most frequently mutated oncogenes ( Figure 5 ), suggesting that deregulated activation of the BMP pathway in uterus epithelial cells is likely a key oncogenic mechanism in at least some cases of endometrium cancers. Interestingly, the ACVR1 mutations and their potential oncogenic roles in endometrium cancers were also discussed in a recent study 13 .
Gene
We recognize the limitations in our study. Since the percentage of cancer somatic mutations overlapping with germline pathogenic variants is small (0.6% of somatic mutations, 1.6% of recurrent somatic mutations in COSMIC; Table 1 ), our approach will not be applicable to the majority of the somatic mutation data from cancer genomic sequencing. Furthermore, identification of putative oncogenes based on high recurrence and mutual exclusivity from known oncogenes yielded few candidates. This is partly due to the fact that very few HGMD/COSMIC overlapping mutations have high recurrence in cancers. In addition, lack of mutual exclusivity with known oncogenes does not necessarily preclude the mutations as cancer drivers. Our goal was only to identify potentially novel cancer genes with high confidence. As more cancer genomic sequencing data become available in COSMIC, our approach will likely lead to the identification of additional putative oncogenes. Another limitation is that most of the candidate cancer genes from our analysis lack apparent functional connection to cancer development. This is somewhat expected due the inherent nature of our approach using Mendelian diseases pathogenic variants to aid novel cancer gene discovery. Accordingly, our study demonstrates a powerful technique for hypothesis generation to identify associations that warrant further experimental validation.
